Can Amygdalin Provide any Benefit in Integrative Anticancer Treatment?

Czech version

Authors: Alžběta Třísková; Jana Rudá-Kučerová
Authors‘ workplace: Farmakologický ústav, LF MU, Brno
Published in: Klin Onkol 2019; 32(5): 360-366
Category: Review
doi: https://doi.org/10.14735/amko2019360

Overview

Background: Amygdalin is a natural compound primarily found in seeds of fruit trees. In the human body, it is hydrolyzed to benzaldehyde, glucose, and cyanide, which is considered the active component of amygdalin. The semi-synthetic form of amygdalin is known under the commercial name Laetrile® or as vitamin B17.

Purpose: This review aims to provide a comprehensive overview of studies that evaluated the potential therapeutic effects of amygdalin in oncology. Preclinical studies provided information about the mechanisms of action of amygdalin in vitro and in vivo and its toxicity. Recent in vitro studies demonstrated the effects of amygdalin on the cell cycle, apoptosis, and synthesis of cyclooxygenase-2, inducible nitric oxide synthase, E-cadherin, and integrins β1 and β4. However, amygdalin exhibited no or low treatment efficiency in preclinical in vivo studies. Conversely, many case studies describe the anti-tumor effects of amygdalin, but these have not been confirmed in clinical trials. Only two clinical studies published almost 40 years ago focused on the safety of amygdalin administered orally and intravenously. Although these studies reported that amygdalin had no benefit in 178 cancer patients, this compound has recently come to the attention of both scientists and patients. The results of recent in vitro studies are promising and indicate that amygdalin has a oncopreventive effect, although this must be confirmed by in vivo studies and clinical trials. Considering its proven toxicity and unconvincing clinical effects, amygdalin cannot currently be recommended to oncology patients as a supportive treatment.

Keywords:

toxicity – side effects – malignancy – amygdalin

Sources

1. Savic IM, Nikolic VD, Savic-Gajic IM et al. Optimization of technological procedure for amygdalin isolation from plum seeds (Pruni domesticae semen). Front Plant Sci 2015; 6: 276. doi: 10.3389/fpls.2015.00 276.

2. Liczbiński P, Bukowska B. Molecular mechanism of amygdalin action in vitro: review of the latest research. Immunopharmacol Immunotoxicol 2018; 40 (3): 212–218. doi: 10.1080/08923973.2018.1441301.

3. Zhou C, Qian L, Ma H et al. Enhancement of amygdalin activated with β-D-glucosidase on HepG2 cells proliferation and apoptosis. Carbohydr Polym 2012; 90 (1): 516–523. doi: 10.1016/j.carbpol.2012.05.073.

4. Milazzo S, Lejeune S, Ernst E. Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer 2007; 15 (6): 583–595. doi: 10.1007/s00520-006-0 168-9.

5. Song Z, Xu X. Advanced research on anti-tumor effects of amygdalin. J Can Res Ther 2014; 10 (Suppl 1): 3–7. doi: 10.4103/0973-1482.139743.

6. Suchard JR, Wallace KL, Gerkin RD. Acute cyanide toxicity caused by apricot kernel ingestion. Ann Emerg Med 1998; 32 (6): 742–744. doi: 10.1016/s0196-0644 (98) 70 077-0.

7. Unproven methods of cancer management. Laetrile. CA Cancer J Clin 1991; 41 (3): 187–192. doi: 10.3322/canjclin.41.3.187.

8. Milazzo S, Horneber M. Laetrile treatment for cancer. Cochrane Database Syst Rev 2015; (4): CD005476. doi: 10.1002/14651858.CD005476.pub4.

9. Milazzo S, Ernst E, Lejeune S et al. Laetrile treatment for cancer. Cochrane Database Syst Rev 2011; (11): CD005476. doi: 10.1002/14651858.CD005476.pub3.

10. Fischer FH, Lewith G, Witt CM et al. High prevalence but limited evidence in complementary and alternative medicine: guidelines for future research. BMC Complement Altern Med 2014; 14: 46. doi: 10.1186/1472-6882-14-46.

11. Saghatchian M, Bihan C, Chenailler C et al. Exploring frontiers: use of complementary and alternative medicine among patients with early-stage breast cancer. Breast 2014; 23 (3): 279–285. doi: 10.1016/j.breast.2014.01. 009.

12. Huebner J, Micke O, Muecke R et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 2014; 34 (2): 943–948.

13. Chang HK, Yang HY, Lee TH et al. Armeniacae semen extract suppresses lipopolysaccharide induced expressions of cyclooxygenase correction of cycloosygenase. 2 and inducible nitric oxide synthase in mouse BV2 microglial cells. Biol Pharm Bull 2005; 28 (3): 449–454. doi: 10.1248/bpb.28.449.

14. Strugala GJ, Stahl R, Elsenhans B et al. Small-intestinal transfer mechanism of prunasin, the primary metabolite of the cyanogenic glycoside amygdalin. Hum Exp Toxicol 1995; 14 (11): 895–901. doi: 10.1177/096032719501401107.

15. Wagner B, Galey WR. Kinetic analysis of hexose transport to determine the mechanism of amygdalin and prunasin absorption in the intestine. J Appl Toxicol 2003; 23 (5): 371–375. doi: 10.1002/jat.934.

16. Rauws AG, Olling M, Timmerman A. The pharmacokinetics of prunasin, a metabolite of amygdalin. J Toxicol Clin Toxicol 1982; 19 (8): 851–856. doi: 10.3109/15563658208992518.

17. Shim SM, Kwon H. Metabolites of amygdalin under simulated human digestive fluids. Int J Food Sci Nutr 2010; 61 (8): 770–779. doi: 10.3109/09637481003796 314.

18. Blaheta RA, Nelson K, Haferkamp A et al. Amygdalin, quackery or cure? Phytomedicine 2016; 23 (4): 367–376. doi: 10.1016/j.phymed.2016.02.004.

19. Lee HM, Moon A. Amygdalin regulates apoptosis and adhesion in Hs578T triple-negative breast cancer cells. Biomol Ther (Seoul) 2016; 24 (1): 62–66. doi: 10.4062/biomolther.2015.172.

20. Chang HK, Shin MS, Yang HY et al. Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull 2006; 29 (8): 1597–1602. doi: 10.1248/bpb.29.1597.

21. Chen Y, Ma J, Wang F et al. Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol Immunotoxicol 2013; 25 (1): 43–51. doi: 10.3109/08923973.2012.738688.

22. Makarevic J, Rutz J, Juengel E et al. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2. PLoS One 2014; 9 (8): e105590. doi: 10.1371/journal.pone.0105590.

23. Qian L, Xie B, Wang Y et al. Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int J Clin Exp Pathol 2015; 8 (5): 5363–5370.

24. Luo H, Li L, Tang J et al. Amygdalin inhibits HSC-T6 cell proliferation and fibrosis through the regulation of TGF-β/CTGF. Mol Cell Toxicol 2016; 12 (3): 265–271. doi: 10.1007/s13273-016-0031-0.

25. Wodinsky I, Swiniarski JK. Antitumor activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumors. Cancer Chemother Rep 1975; 59 (5): 939–950.

26. Laster WR Jr, Schabel FM Jr. Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). Cancer Chemother Rep 1975; 59 (5): 951–965.

27. Ovejera AA, Houchens DP, Barker AD et al. Inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice. Cancer Treat Rep 1978; 62 (4): 576–578.

28. Hill GJ, Shine TE, Hill HZ et al. Failure of amygdalin to arrest B16 melanoma and BW5147 AKR leukemia. Cancer Res 1976; 36 (6): 2102–2107.

29. Stock CC, Tarnowski GS, Schmid FA et al. Antitumor tests of amygdalin in transplantable animal tumor systems. J Surg Oncol 1978; 10 (2): 81–88. doi: 10.1002/ jso.2930100202.

30. Manner HW, DiSanti SJ, Maggio MI et al. Amygdalin, vitamin A and enzyme induced regression of murine mammary adenocarcinomas. J Manipulative Physiol Ther 1978; 1 (4): 246–248.

31. Morrone JA. Chemotherapy of inoperable cancer: preliminary report of 10 cases treated with laetrile. Exp Med Surg 1962; 20: 299–308.

32. Navarro MD. Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contra Cancum 1959; 15 (Suppl 1): 209–221.

33. Navarro MD. Laetrile therapy in cancer. Acta Unio Int Contra Cancrum 1964; 20: 392–394.

34. Weber P. Influence of amygdalin treatment on clinical progress and tumor relevant serum enzymes in 29 cancer patients. In: Doctoral thesis. Medical Faculty of the Georg August-University Göttingen. Germany 1975.

35. Rossi B, Guidetti E, Deckers C. A clinical trial of chemotherapeutic treatment of advanced cancers with L-mandelonitrile -diglucoside (abstract). In: 9th International Cancer Congress. Japan: Tokyo 1996.

36. Moertel CG, Ames MM, Kovach JS et al. A pharmacologic and toxicological study of amygdalin. JAMA 1981; 245 (6): 591–594.

37. Moertel CG, Fleming TR, Rubin J et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982; 306 (4): 201–206. doi: 10.1056/NEJM198201283060403.

38. PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Laetrile/Amygdalin (PDQ®): Patient Version. [online]. Available from http: //www.ncbi.nlm.nih.gov/books/NBK65722/.

39. Bromley J, Hughes BG, Leong DC et al. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 2005; 39 (9): 1566–1569. doi: 10.1345/aph.1E634.

40. Todorova A, Pesheva M, Iliev I et al. Antimutagenic, antirecombinogenic, and antitumor effect of amygdalin in a yeast cell-based test and mammalian cell lines. J Med Food 2017; 20 (4): 360–366. doi: 10.1089/jmf.2016.0 108.

41. Wisniak J, Robiquet PJ. Emergent topics on chemistry education. Educ Quimica 2013; 24 (1): 139–149.

42. Dorr RT, Paxinos J. The current status of laetrile. Ann Intern Med 1978; 89 (3): 389–397. doi: 10.7326/0003-4819-89-3-389.

43. Moss RW. The laetrile controversy. In: Moss RW (ed). The Cancer Industry: The Classic Expose on the Cancer Establishment. New York: First Equinox Press 1996: 131–152.

44. Curt GA. Unsound methods of cancer treatment. Princ Pract Oncol Updates 1990; 4 (12): 1–10.

45. Moss RW. Patient perspectives: Tijuana cancer clinics in the post-NAFTA era. Integr Cancer Ther 2005; 4 (1): 65–86. doi: 10.1177/1534735404273918.

46. Davignon JP, Trissel LA, Kleinman LM. Pharmaceutical assessment of amygdalin (Laetrile) products. Cancer Treat Rep 1978; 62 (1): 99–104.

47. Curran WJ. Law-medicine notes. Laetrile for the terminally ill: Supreme Court stops the nonsense. N Engl J Med 1980; 302 (11): 619–621. doi: 10.1056/NEJM198 003133021108.